HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Pushes For OTC Exemption In California’s Green Regs

This article was originally published in The Rose Sheet

Executive Summary

The Personal Care Products Council and the Consumer Healthcare Products Association call for the California Department of Toxic Substances Control to specifically exclude OTC drugs from its Safer Consumer Products regulation, part of the state’s Green Chemistry Initiative. Including OTC drugs in the regulation would duplicate oversight and “run counter to the mandates of [FDA],” the groups argue.

You may also be interested in...



Personal Care Not Likely First Target Of California Consumer Product Regs

A new draft of California’s Safer Consumer Product Regulations could change how the state’s Department of Toxic Substances Control selects priority products for potential reformulation. DTSC may now select products for review only if they contain chemicals of concern that meet new criteria, which may exclude many substances found in personal-care products, according to PCPC’s Tom Myers.

California Refines Consumer Products Regs, Exempting Trace Contaminants

California’s Department of Toxic Substances Control has released the next draft of its Safer Consumer Products Regulations, taking into consideration comments from stakeholders.

In Brief

According to NPD Group, prestige fragrance sales at department stores are up 7% through October and are among the top holiday gifts for consumers. More news in brief.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel